Erratum: In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL

Correction to: Cancer Gene Therapy (2004) doi: 10.1038/sj.cgt.7700678; Published Online: 23 January 2004

Due to a typesetting error, Figure 2 was published incomplete. The complete Figure 2 is printed below.

Figure 2

Sensitivity of the cells to FasL and TRAIL. (a) [³⁵S] methionine labeled target cells (5 × 10⁵ cells/ml) were coincubated with FasL-expressing cells (39.5-B7-FasL) or with nonexpressor (39.5-B7) for 18 h and release of radioactivity was monitored. L1210-fas cells were used as a positive control. The data represent average±SD of triplicate in one of three independent experiments. (b) Expression of mTRAIL receptor (DR5) on parental D122 and cytokine transfectants (NAT.A, DIF-2 and DIL6-7) was tested according to Materials and methods. (c) Cells (1 × 10⁶ cells) were incubated with sTRAIL (100 ng/ml) overnight, and cells were analyzed by flow cytometry after staining with Annexin and PI. The data shows one of two independent experiments.

On page 244, 18 lines of text were printed in error. The sentence should read correctly as “The results in Figure 7a show that local tumors of C57BL/6 and B6-PKO mice significantly progressed when the mice were depleted from the CD8 T-cell subpopulation.”